MorphoSys AG (MOR)
Aug 5, 2024 - MOR was delisted (reason: voluntary delisting)
18.96
+0.45 (2.43%)
Inactive · Last trade price
on Aug 2, 2024
MorphoSys AG Revenue
MorphoSys AG had revenue of $27.54M in the quarter ending March 31, 2024, with 13.11% growth. This brings the company's revenue in the last twelve months to $241.47M, down -7.53% year-over-year. In the year 2023, MorphoSys AG had annual revenue of $238.28M, down -14.37%.
Revenue (ttm)
$241.47M
Revenue Growth
-7.53%
P/S Ratio
10.79
Revenue / Employee
$505,255
Employees
524
Market Cap
2.86B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 238.28M | -39.99M | -14.37% |
| Dec 31, 2022 | 278.27M | 98.66M | 54.93% |
| Dec 31, 2021 | 179.61M | -148.09M | -45.19% |
| Dec 31, 2020 | 327.70M | 255.94M | 356.69% |
| Dec 31, 2019 | 71.76M | -4.69M | -6.13% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionMOR News
- 5 hours ago - Novartis: launch of Morphosys drug by could be 2027 or later - Reuters
- 3 months ago - Merger Squeeze-Out of MorphoSys Minority Shareholders Approved at 2024 Annual General Meeting - Accesswire
- 4 months ago - MorphoSys Announces Voluntary Delisting from the Nasdaq Global Market - Business Wire
- 5 months ago - MorphoSys and Novartis Sign Delisting Agreement and Intend to Implement a Merger Squeeze-out of MorphoSys' Minority Shareholders - Business Wire
- 5 months ago - Ad hoc: Novartis BidCo Germany AG Intends to Implement a Merger Squeeze-out of MorphoSys AG's Minority Shareholders - Accesswire
- 6 months ago - Novartis meets all tender offer conditions to acquire MorphoSys AG for EUR 68 per share in cash - GlobeNewsWire
- 7 months ago - MorphoSys: Hold Rating Until The Novartis Deal Closes - Seeking Alpha
- 7 months ago - MorphoSys AG Reports First Quarter 2024 Financial Results - Business Wire